Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting
September 21, 2021

The ODM DUR Board meeting was called to order at 12:04 PM EST via GoToMeeting
https://attendee.gotowebinar.com/register/4124977711676393740
ODM Pharmacy Staff and DUR Board members attended in person at:
Ohio Department of Medicaid, 50 West Town Street, Room A535

Stacey Rexrode-Brewer Pharm.D. presided

The following Board members were present:
Scott Baran, R.Ph.
Michael Dietz, D.O.
Michael Farrell, M.D., Co-Chair
A. Mehran Mostafavifar, M.D.
Stacey Rexrode-Brewer Pharm.D., Chair

Also present from ODM were Michelle Barger, Pharm. D., Sean Eckard, B.S. Pharm.D., Yana Doughty, Pharm.D., and Brian Gallow, Pharm.D. Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm. D., Gail Master, R.Ph., and Philip Verret, Pharm. D. Approximately 44 observers were present.

The Conflict of Interest Statement

The Conflict of Interest Statement was reviewed with the Board.

Roll Call and Review of Previous Minutes

The May 11, 2021 DUR Board Meeting Minutes were approved.

DUR Committee Report

G. Master presented the re-review results from the opioids and gabapentin intervention. This intervention resulted in sixty two percent of members using less opioid or gabapentin. Next, G. Master presented the re-review results from the opioids and stimulants intervention. This intervention resulted in seventy one percent of members using less opioid or stimulant. She then presented the intervention and responses from prescribers whose patients were eighteen years old or younger who were receiving opioids. Next, G. Master presented the intervention and responses from prescribers whose patients were taking chronic triptan therapy without prophylactic medication. She then informed the Board that the most recent 2021 Vol 16 DUR Digest had been posted to the Ohio Medicaid Pharmacy Website and presented the contents of the Digest. Next, G. Master presented the program where every month, prescribers and pharmacists are called whose patients are taking either medication assisted therapy (MAT) and opioids or MAT and benzodiazepines concomitantly the previous month. The prescribers’ and pharmacists’ responses were presented.
Lastly, G. Master provided an update to the Board on Coordinated Services Program (CSP) membership. There are currently 220 Fee-for-Service members enrolled in the program.

Health Plan Policy Update

S. Baran presented the Ohio Medicaid Health Plan Policy update. The Ohio Department of Medicaid announced last month that Ohio Medicaid’s Next Generation managed care is projected to go-live on July 1, 2022. The Next Generation program introduces 5 new components: Managed Care, OhioRISE, Single Pharmacy Benefit Manager (SPBM), Centralized Credentialing, and Fiscal Intermediary (FI). The final selection of future managed care organizations includes UnitedHealthcare Community Plan of Ohio, Humana Health Plan of Ohio, Molina Healthcare of Ohio, AmeriHealth Caritas Ohio, Anthem Blue Cross and Blue Shield, CareSource Ohio, and Buckeye Health Plan.

Next, S. Baran stated that ODM continues to be proactive in ensuring access to COVID-19 vaccines during the public health emergency. Enrolled pharmacies can now submit electronic NCPDP claims for COVID-19 vaccine booster administration for both Moderna and Pfizer vaccines. ODM will reimburse $37.98 for each additional dose of vaccine administered.

Also announced at the September meeting, as previously announced, ODM has begun reimbursing pharmacists as Medicaid providers and continues to enroll pharmacists into the Medicaid program as full providers. Currently, over 860 pharmacists have enrolled. These enrolled pharmacists represent a diverse range of practice settings, including independent practitioners, retail/community pharmacy, hospital and health system pharmacy, and clinics.

Next, over the summer, ODM launched its redesigned website (www.medicaid.ohio.gov). The refreshed design shifts the focus to the individual member with a more personalized care experience and advances the goal of moving ODM to the new Innovate Ohio Platform (IOP) along with other state agencies. The new site is streamlined for optimized use on multiple web platforms and, for the first time, on mobile devices.

Lastly, the next Pharmacy and Therapeutics (P&T) Committee meeting will take place on October 6th beginning at 9am. This is the annual meeting where the Committee reviews the entire Unified Preferred Drug List (UPDL) document. The meeting will be held in a hybrid format with ODM Pharmacy Staff and P&T Committee members attending in-person while the public audience attends virtually. Business discussed during the October meeting will go into effect January 1st.

Unfinished Business

There was no unfinished business.

New Business

G. Master presented an overview of a RetroDUR intervention directed at prescribers whose patients were receiving multiple anticholinergic medications. The purpose of this intervention was to alert prescribers whose patients were taking multiple anticholinergic medications or being prescribed these medications by multiple prescribers of the undesired additive effects.

Open Discussion

There were no issues to discuss.

Announcements
The 2021 calendar was reviewed.

Dates for the 2021 and 2022 DUR Board meetings were set as follows:

- November 9, 2021
- February 8, 2022
- May 10, 2022
- September 13, 2022
- November 8, 2022

Adjournment

The meeting was adjourned at 12:42 PM.